Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer
Ovidio Fernández Calvo, José Muñoz Iglesias, Estephany Abou Jokh Casas, Aura Molina-Díaz, Urbano Anido Herranz, Javier Casas Nebra, Lucía García-Bernardo, Sara Martínez-Breijo, Martín Lázaro-Quintela, Gloria Muñiz-García, Sergio Vázquez-Estevez
{"title":"Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer","authors":"Ovidio Fernández Calvo, José Muñoz Iglesias, Estephany Abou Jokh Casas, Aura Molina-Díaz, Urbano Anido Herranz, Javier Casas Nebra, Lucía García-Bernardo, Sara Martínez-Breijo, Martín Lázaro-Quintela, Gloria Muñiz-García, Sergio Vázquez-Estevez","doi":"10.1007/s12094-024-03662-7","DOIUrl":null,"url":null,"abstract":"<p>Theragnostic is a type of precision medicine that uses molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. In recent years, it has gained significant importance to treat neuroendocrine tumors and is currently being used in prostate cancer. Various radiopharmaceuticals have emerged for diagnosing and detecting lesions showing prostate-specific membrane antigen (PSMA) positivity on the Positron emission tomography/computed tomography scan, being the most widely used labeled with [<sup>68</sup>Ga] and [<sup>18</sup>F]. Its use as therapy in prostate cancer (PC) has been assessed in the VISION, TheraP, and PSMAfore clinical trials conducted with the radioligand [<sup>177</sup>Lu]Lu-PSMA-617, demonstrating significant antitumor activity. The aim of this article is to present practical recommendations, based on current available scientific evidence and on a multidisciplinary consensus, for the diagnosis and treatment with [<sup>177</sup>Lu]Lu-PSMA-617 in patients with PC.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12094-024-03662-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Theragnostic is a type of precision medicine that uses molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. In recent years, it has gained significant importance to treat neuroendocrine tumors and is currently being used in prostate cancer. Various radiopharmaceuticals have emerged for diagnosing and detecting lesions showing prostate-specific membrane antigen (PSMA) positivity on the Positron emission tomography/computed tomography scan, being the most widely used labeled with [68Ga] and [18F]. Its use as therapy in prostate cancer (PC) has been assessed in the VISION, TheraP, and PSMAfore clinical trials conducted with the radioligand [177Lu]Lu-PSMA-617, demonstrating significant antitumor activity. The aim of this article is to present practical recommendations, based on current available scientific evidence and on a multidisciplinary consensus, for the diagnosis and treatment with [177Lu]Lu-PSMA-617 in patients with PC.
热诊断是一种利用与放射性同位素相连的分子来诊断和治疗疾病的精准医学。近年来，它在治疗神经内分泌肿瘤方面发挥了重要作用，目前正被用于前列腺癌的治疗。正电子发射断层扫描/计算机断层扫描扫描显示前列腺特异性膜抗原（PSMA）阳性的病变诊断和检测出现了多种放射性药物，其中使用最广泛的是标记有[68Ga]和[18F]的药物。在使用放射性配体[177Lu]Lu-PSMA-617进行的VISION、TheraP和PSMAfore临床试验中，对其作为前列腺癌（PC）的治疗方法进行了评估，结果显示其具有显著的抗肿瘤活性。本文旨在根据现有科学证据和多学科共识，就 PC 患者使用[177Lu]Lu-PSMA-617 进行诊断和治疗提出实用建议。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
